• 1
    Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 14718.
  • 2
    Bodger K. Cost of illness of Crohn’s disease. Pharmacoeconomics 2002; 20: 63952.
  • 3
    Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 4957.
  • 4
    Bodger K. Economic implications of biological therapies for Crohn’s disease: review of infliximab. Pharmacoeconomics 2005; 23: 87588.
  • 5
    National Institute for Health & Clinical Excellence (NICE). Appraisal consultation document: Infliximab (review) and adalimumab for the treatment of Crohn’s disease (including a review of technology appraisal guidance 40). . 2008
  • 6
    Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr. Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology 2001; 120: 164056.
  • 7
    Clark W, Raftery J, Song F, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease. Health Technol Assess 2003; 7: 167.
  • 8
    Jaisson-Hot I, Flourie B, Descos L, Colin C. Management for severe Crohn’s disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004; 20: 2749.
  • 9
    Marshall JK, Blackhouse G, Goeree R, Brazier N, Irvine EJ, O’Brien BJ. Clinical and economic assessment: infliximab for the treatment of Crohn’s disease: technology overview. 8. 2008. Ottawa, Canadian Coordinating Office for Health Technology Assessment (CCOHTA).
  • 10
    Buxton MJ, Lacey LA, Feagan BG, Niecko T, Miller DW, Townsend RJ. Mapping from disease-specific measures to utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn’s Disease Activity Index in Crohn’s disease and measures of utility. Value Health 2007; 10: 21420.
  • 11
    Jess T, Loftus EV Jr, Harmsen WS, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940–2004. Gut 2006; 55: 124854.
  • 12
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 13
    Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 105461.
  • 14
    Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117: 7619.
  • 15
    Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004; 126: 40213.
  • 16
    Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337: 102935.
  • 17
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 32333.
  • 18
    Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 56: 12329.
  • 19
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132: 5265.
  • 20
    Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology 2005; 128: 8629.
  • 21
    Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohn’s disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005; 17: 104752.
  • 22
    Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 62130.
  • 23
    Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn’s disease. Aliment Pharmacol Ther 2007; 25: 86170.
  • 24
    Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313: 27583.
  • 25
    Curtis L. Unit Costs of Health and Social Care 2007. Canterbury, United Kingdom: Personal Social Services Reseach Unit, University of Kent. 2008, 1208.
  • 26
    Joint Formulary Committee. British National Formulary. 53rd edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2008.
  • 27
    Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn’s disease. Gastroenterology 2001; 121: 26874.
  • 28
    Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005; 353: 191225.
  • 29
    National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. Available online. 2008.
  • 30
    Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease – modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 2008; 28: 7687.
  • 31
    Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 Crohn’s disease patients: results from a single centre cohort. Gut 2009; 58: 492500.
  • 32
    Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology 2008; 135: 14939.
  • 33
    Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn’s disease. J Clin Gastroenterol 2002; 35: 1516.
  • 34
    Schnitzler F, Fidder H, Ferrante M, et al. Infliximab therapy for refractory Crohn’s Disease (CD) decreases the long-term need for bowel surgery. Gastroenterology 2008; 134: A134. (Abstract).